Henry S H Chan1, Christine I Chen1, Donna E Reece2. 1. Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada. 2. Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada. Donna.Reece@uhn.ca.
Abstract
PURPOSE OF REVIEW: New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians. RECENT FINDINGS: Apart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment. Recent introduction of combination therapy with proteasome inhibitors and immunomodulatory drugs is showing promising results in high-risk patients and may partially abrogate the negative impact associated with some of the adverse risk factors. Recent advance has improved our understanding of high-risk multiple myeloma, and new therapeutic agents are now coming through the pipeline for this patient group with once dismal outcome.
PURPOSE OF REVIEW: New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians. RECENT FINDINGS: Apart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment. Recent introduction of combination therapy with proteasome inhibitors and immunomodulatory drugs is showing promising results in high-risk patients and may partially abrogate the negative impact associated with some of the adverse risk factors. Recent advance has improved our understanding of high-risk multiple myeloma, and new therapeutic agents are now coming through the pipeline for this patient group with once dismal outcome.
Entities:
Keywords:
High risk; Multiple myeloma; Novel agents; del(17p); t(4;14)
Authors: R Kuiper; A Broyl; Y de Knegt; M H van Vliet; E H van Beers; B van der Holt; L el Jarari; G Mulligan; W Gregory; G Morgan; H Goldschmidt; H M Lokhorst; M van Duin; P Sonneveld Journal: Leukemia Date: 2012-05-08 Impact factor: 11.528
Authors: P Moreau; M Attal; F Garban; C Hulin; T Facon; G Marit; M Michallet; C Doyen; S Leyvraz; M Mohty; M Wetterwald; C Mathiot; D Caillot; C Berthou; L Benboubker; L Garderet; C Chaleteix; C Traullé; J G Fuzibet; J Jaubert; T Lamy; P Casassus; M Dib; B Kolb; V Dorvaux; B Grosbois; I Yakoub-Agha; J L Harousseau; H Avet-Loiseau Journal: Leukemia Date: 2007-07-12 Impact factor: 11.528
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan Journal: Leukemia Date: 2012-10-03 Impact factor: 11.528
Authors: Ambuj Kumar; Mohamed A Kharfan-Dabaja; Axel Glasmacher; Benjamin Djulbegovic Journal: J Natl Cancer Inst Date: 2009-01-13 Impact factor: 13.506
Authors: Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski Journal: Blood Date: 2002-10-03 Impact factor: 22.113
Authors: Rafael Ríos-Tamayo; Juan Sáinz; Joaquín Martínez-López; José Manuel Puerta; Daysi-Yoe-Ling Chang; Teresa Rodríguez; Pilar Garrido; José Luís García de Veas; Antonio Romero; Lucía Moratalla; Elisa López-Fernández; Pedro Antonio González; María José Sánchez; José Juan Jiménez-Moleón; Manuel Jurado; Juan José Lahuerta Journal: Am J Hematol Date: 2016-04-28 Impact factor: 10.047
Authors: Ajai Chari; Robert F Cornell; Cristina Gasparetto; Chatchada Karanes; Jeffrey V Matous; Ruben Niesvizky; Matthew Lunning; Saad Z Usmani; Larry D Anderson; Saurabh Chhabra; Saulius Girnius; Chaim Shustik; Robert Stuart; Yihua Lee; Zeena Salman; Emily Liu; Jason Valent Journal: Hematol Oncol Date: 2020-03-11 Impact factor: 5.271